ClinicalTrials.gg
Active, not recruitingNCT06289452Updated Nov 4, 2026

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis

An Early Phase 1 interventional study of IVB102 Injection and IVB102 Injection in Retinoschisis, Retinal Disease and Retinal Degeneration, sponsored by InnoVec Biotherapeutics Inc.. Active, not recruiting at 1 site in China. Open to male participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by InnoVec Biotherapeutics Inc. · Early Phase 1, Interventional, and Treatment

How we know

Updated Nov 4, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
8 Years and older
Sex
Male
01

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.

Read the detailed description

This is a open label, dose escalation, single-center study. One eye of each participant will receive a single IVB102 injection by intravitreal injection. Participants will be followed for 52 weeks after which they will continue to be followed for up to 5 years after enrollment.

02

Conditions studied

  • Retinoschisis
  • Retinal Disease
  • Retinal Degeneration
  • Eye Diseases
03

In context

Retinoschisis

19 studies on the registry are indexed under Retinoschisis; 5 are open to participants now.

This study's planned enrollment of 18 is close to the median of 19 across 12 interventional studies indexed under Retinoschisis.

Browse Retinoschisis studies →

Lead sponsor

InnoVec Biotherapeutics Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be willing and able to provide written, signed .
  2. Male individual at least 8 years of age with clinical diagnosis of XLRS caused by mutations in RS1.
  3. Best corrected visual acuity (BCVA) in the study eye of less than or equal to 63 (corresponding to a Snellen acuity of 20/63).
  4. Must agree to use effective barrier (male or female condom) of before dosing and continuing one year after gene transfer.

Exclusion criteria

Exclusion Criteria:

  1. Lens, cornea, or other media opacities in the study eye that preclude adequate visualization and testing of the retina.
  2. Pre-existing eye conditions that would contribute significantly to visual loss or increase the risk of an intravitreal injection (e.g. DR、RVO or large retinal detachment).
  3. Any intraocular surgery in the study eye within 6 months prior to screening.
  4. Use of topical carbonic anhydrase inhibitors within 3 months prior to screening.
  5. Use of anticoagulants or anti- agents within 7 days prior to study agent administration.
  6. Prior receipt of any AAV gene therapy product.
  7. Use of any agent within 3 months prior to screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    IVB102 Treatment Arm(Low dose)

    Intraocular injection of a single low dose of IVB102

    Genetic: IVB102 Injection

  • Experimental
    IVB102 Treatment Arm(Intermediate dose)

    Intraocular injection of a single intermediate dose of IVB102

    Genetic: IVB102 Injection

  • Experimental
    IVB102 Treatment Arm(High dose)

    Intraocular injection of a single high dose of IVB102

    Genetic: IVB102 Injection

Interventions

  • GeneticIVB102 Injection

    Gene transfer by intravitreal injection of the RS1 AAV vector

  • GeneticIVB102 Injection

    Gene transfer by intravitreal injection of the RS1 AAV vector

  • GeneticIVB102 Injection

    Gene transfer by intravitreal injection of the RS1 AAV vector

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    Number and proportion of dose limited toxicity(DLTs)

    Time frame: 4 weeks

  2. Incidence of AEs

    Number and severity of overall and ocular Adverse Events (AEs)

    Time frame: 52 weeks

  3. Incidence of SAEs

    Number and severity of overall and ocular Serious Adverse Events (SAEs)

    Time frame: 52 weeks

Secondary outcomes

  1. Visual function

    Change from baseline in BCVA(Best Corrected Visual Acuity)(ETDRS)

    Time frame: 52 weeks

  2. OCT imaging

    Change from baseline in CST(Central Retinal Thickness)(OCT)

    Time frame: 52 weeks

  3. ERG parameters

    Change from baseline in response amplitudes measured using Electroretinogram (ERG)

    Time frame: 52 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Pimenides D, George ND, Yates JR, Bradshaw K, Roberts SA, Moore AT, Trump D. X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients. J Med Genet. 2005 Jun;42(6):e35. doi: 10.1136/jmg.2004.029769. PubMed 15937075 ↗
  • Wang XF, Chen FF, Zhou X, Cheng XX, Xie ZG. A novel mutation in RS1 and clinical manifestations in a Chinese twin family with congenital retinoschisis. Front Genet. 2022 Sep 23;13:993157. doi: 10.3389/fgene.2022.993157. eCollection 2022. PubMed 36212125 ↗
  • Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007 Apr;44(4):225-32. doi: 10.1136/jmg.2006.047340. Epub 2006 Dec 15. PubMed 17172462 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Dec 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2024
First posted
Mar 1, 2024
StartActual
Mar 8, 2024
Primary completionActual
Dec 31, 2025
CompletionEst.
Dec 31, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Peking Union Medical College Hospital · Beijing, China
Show 1 removed
  • Peking Union Medical College Hospital · Beijing, China
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • Peking Union Medical College Hospital · Beijing, China
    Show 1 removed
    • Peking Union Medical College Hospital · Beijing, China
    + 4 other changes: verification date, date precision, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06289452
Lead sponsor
InnoVec Biotherapeutics Inc.
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Mar 8, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2029 (estimated)
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion